title: Reversal of SSRI-associated urinary retention with mirtazapine augmentation.
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Lenze
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008803:Mianserin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000078785:Mirtazapine; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D016055:Urinary Retention / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000317:Adrenergic alpha-Antagonists; D014151:Anti-Anxiety Agents; D000929:Antidepressive Agents, Tricyclic; D015283:Citalopram; D008803:Mianserin; D000078785:Mirtazapine; D017367:Selective Serotonin Reuptake Inhibitors